Compare Citius Pharmaceuticals Inc (CTXR) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Consumer Staples Select Sector SPDR Fund trades at $83.46. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | XLP | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $90.00 |
52-Week Low | $0.53 | $75.61 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.58, up 0.55% with a bullish technical signal from moving averages. The ETF holds 36 consumer staples stocks and offers a 2.6% dividend yield. Analyst consensus is strongly positive with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid market uncertainty, with retail sales hitting 12-month highs supporting the sector.
XLP presents a defensive investment opportunity with stable dividend income and low volatility characteristics. The fund's concentrated portfolio of essential consumer goods companies provides resilience during market downturns. Key risks include sector rotation away from defensive stocks and potential margin pressure from inflation. Current technical strength and positive analyst sentiment support near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
